While this method is generally reliable, as it is unlikely that ALK TKIs would be administered without an ALK rearrangement, it limited the study to patients who received ALK TKI treatment and excluded those with ALK-positive NSCLC who might have adhered to other treatment regimens. This evidence concerns the gene ALK and non-small cell lung carcinoma.